J
Joachim Mankertz
Researcher at Charité
Publications - 46
Citations - 7538
Joachim Mankertz is an academic researcher from Charité. The author has contributed to research in topics: Tight junction & Occludin. The author has an hindex of 33, co-authored 43 publications receiving 7004 citations. Previous affiliations of Joachim Mankertz include Free University of Berlin & Robert Koch Institute.
Papers
More filters
Journal ArticleDOI
Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease
Sebastian Zeissig,Nataly Bürgel,Dorothee Günzel,Jan F. Richter,Joachim Mankertz,Ulrich Wahnschaffe,Anton J. Kroesen,Martin Zeitz,Michael Fromm,Joerg D. Schulzke +9 more
TL;DR: Upregulation of pore-forming claudin 2 and downregulation and redistribution of sealing claudins 5 and 8 lead to altered tight junction structure and pronounced barrier dysfunction already in mild to moderately active Crohn’s disease.
Journal ArticleDOI
Interleukin-13 Is the Key Effector Th2 Cytokine in Ulcerative Colitis That Affects Epithelial Tight Junctions, Apoptosis, and Cell Restitution
Frank Heller,Peter Florian,Christian Bojarski,Jan F. Richter,Melanie Christ,Bernd Hillenbrand,Joachim Mankertz,Alfred H. Gitter,Nataly Bürgel,Michael Fromm,Martin Zeitz,Ivan J. Fuss,Warren Strober,Jörg D. Schulzke +13 more
TL;DR: IL-13 was identified as an important effector cytokine in UC that impairs epithelial barrier function by affecting epithelial apoptosis, tight junctions, and restitution velocity.
Journal ArticleDOI
Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells.
Salah Amasheh,Noga Meiri,Alfred H. Gitter,Torsten Schöneberg,Joachim Mankertz,Jörg D. Schulzke,Michael Fromm +6 more
TL;DR: In this paper, the contribution of claudin-2 to barrier and permeability properties of the tight junction in detail was investigated in two strains of Madin-Darby canine kidney cells (MDCK-C7 and MDCKC11) with different tight junctional permeabilities.
Journal ArticleDOI
Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6.
H. Schmitz,Michael Fromm,Carl J. Bentzel,Peter Scholz,Katharina Detjen,Joachim Mankertz,Hagen Bode,Hans-Jörg Epple,Ernst-Otto Riecken,Jörg-Dieter Schulzke +9 more
TL;DR: TNFalpha impairs epithelial barrier function by altering structure and function of the tight junction, which could be of pathogenic relevance in intestinal inflammation.
Journal ArticleDOI
Downregulation of epithelial apoptosis and barrier repair in active Crohn’s disease by tumour necrosis factor α antibody treatment
Sebastian Zeissig,Christian Bojarski,N. Buergel,Joachim Mankertz,Martin Zeitz,Michael Fromm,Joerg-Dieter Schulzke +6 more
TL;DR: Epithelial apoptoses were upregulated in the colon in CD and restored to normal in 10 of 11 patients by TNF-α antibody therapy, which is the structural correlate of epithelial barrier dysfunction measured as epithelial resistance while expression of tight junction proteins did not contribute to this therapeutic effect.